Clinical Trials for Women’s Cancers

Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of ongoing research.

The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.

Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.

Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.

The following clinical trials are open to enrollment.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Type of CancerProtocol ID & Study Title
Cancer PreventionNRG-CC008
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma

Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs
Endometrial GOG-3041-AZD9311C00001-DUO
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

Keywords: Paclitaxel, Docetaxel, Bevacizumab, Carboplatin, Pembrolizumab, Olaparib
An Open Label, Non-Randomized Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

Keywords: Recurrent Endometrial Cancer, Bevacizumab, Atezolizumab, Rucaparib
Endometrial NRG-GY020
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Keywords: Endometrial Neoplasms, Endometrioid Carcinoma, Adenocarcinoma, Glandular and Epithelial Neoplasms, Uterine Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Ovarian Neoplasms, Pembrolizumab
Epithelial Ovarian Cancer (EOC)GOG-3036-MERCK-7339-001
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CELSION-201-17-201
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Epithelial Ovarian, Peritoneal, Fallopian TubeIMMUNOGEN-IMGN853-0417-SORAYA

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Keywords: Platinum resistant, Folate-receptor alpha expression, Phase 3, Antibody-drug conjugate, mirvetuximab soravtansine, IMGN853, Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, MIRV, FRα
Ovarian GOG-3018-VBL-VB-111-701
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

Keywords: Recurrent Ovarian cancer, Platinum resistant ovarian cancer, Ovarian cancer, Ovarian carcinoma, Epithelial ovarian cancer, paclitaxel
A Phase Ib Study of Cobimetinib Administered In Combination with Niraparib, with or without Atezolizumab, to Patients with Advanced Platinum-Sensitive Ovarian Cancer

Keywords: Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Endocrine Gland Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Glandular and Epithelial Neoplasms
A Phase 2 Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

Keywords: Ovarian Cancer, Clear Cell, Recurrent, Persistent, Pembrolizumab and Epacadostat
Ovarian and EndometrialSutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
Recurrent Platinum Sensitive Ovarian CancerRoche Y040482
A phase IB study of cobimetinib administered in combination with niraparib, with or without atezolizumab, to patients with advanced platinum-sensitive ovarian cancer

Keywords: Ovarian, Platinum Sensitive, Recurrent, Cobimetinib, Niraparib, Atezolizumab, Parp Inhibitor, Immunotherapy, Phase 1